Cargando…
Modelling population-level impact to inform target product profiles for childhood malaria vaccines
BACKGROUND: The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program. Work is ongoing to optimise this vaccine, with higher eff...
Autores principales: | Hogan, Alexandra B., Winskill, Peter, Verity, Robert, Griffin, Jamie T., Ghani, Azra C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044028/ https://www.ncbi.nlm.nih.gov/pubmed/30001708 http://dx.doi.org/10.1186/s12916-018-1095-6 |
Ejemplares similares
-
Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa
por: Winskill, Peter, et al.
Publicado: (2017) -
Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study
por: Hogan, Alexandra B., et al.
Publicado: (2020) -
Analysis of the potential for a malaria vaccine to reduce gaps in malaria intervention coverage
por: Unwin, H. Juliette T., et al.
Publicado: (2021) -
The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study
por: Winskill, Peter, et al.
Publicado: (2017) -
Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials
por: White, Michael T, et al.
Publicado: (2010)